Clinical Trials Directory

Trials / Completed

CompletedNCT01080456

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting Condition

A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 1 mg in Normal Healthy Male Subjects Under Fasting Condition

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Panacea Biotec Ltd · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg, manufactured by Panacea Biotec Limited, India and the corresponding Reference Product (B): Prograf (Tacrolimus) Capsules 1 mg, manufactured by Astellas Pharma, Inc., USA in 36 normal, healthy, adult, male subjects under fasting condition.

Detailed description

Total 36 normal healthy adult male subjects will be enrolled in the study. Subjects will be administered either the Test or the Reference Product with 240 mL of water in each period as per the randomization schedule. Subjects will fast for at least 10 hours prior to dose administration and for at least 4 hours post dose. Standardized meals will be provided in each study period. Water will not be accessible to the subjects 1 hour Predose and 2 hours Post dose in each period. A total of 23 blood samples will be withdrawn for pharmacokinetic profiling. The whole blood concentrations of Tacrolimus will be measured by a validated LC/MS/MS analytical method. Ratio analysis will be performed for untransformed and log transformed pharmacokinetic parameters Cmax, AUC0-72, AUC0 inf. ANOVA will be performed on log transformed pharmacokinetic parameters Cmax, AUC0-72, AUC0-inf and 90% confidence interval will be constructed for the ratio of geometric least square mean of the Test and Reference products, obtained from the log-transformed data. Bioequivalence will be concluded if the ratio estimate as well as its 90% confidence interval, both falls within the acceptable range of 80.00% to 125.00% for Cmax, AUC0-72 and AUC0-inf.

Conditions

Interventions

TypeNameDescription
DRUGTacrolimus 1 mg capsuleSubjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule

Timeline

Start date
2007-09-01
Primary completion
2007-10-01
Completion
2007-10-01
First posted
2010-03-04
Last updated
2010-03-04

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT01080456. Inclusion in this directory is not an endorsement.